Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future PerspectivesMattia Longoni, Marco Moschini, Andrea Gallioli et al.|European Urology Oncology|2025Cited by 43
Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group CollaborationFrancesco Soria, Paolo Gontero, Matteo Rosazza et al.|European Urology Oncology|2024Cited by 32
The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysisPietro Scilipoti, Marco Moschini, Aleksander Ślusarczyk et al.|European Urology Oncology|2024Cited by 29
Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational StudyMaximilian Pallauf, Benjamin Pradère, David D‘Andrea et al.|The Journal of Urology|2022Cited by 24
Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic reviewGiuseppe Basile, Roberto Carando, Mario de Angelis et al.|Minerva Urology and Nephrology|2023Cited by 18